Last edition
News about "Oncology"
FDA Grants Orphan Drug Status to HanchorBio's HCB101 for Gastric Cancer
The Orphan Drug Status designation to HanchorBio supports development of next-generation CD47–SIRPα immunotherapy for advanced gastric adenocarcinoma across HER2-positive and HER2-negative subtypes.
Oncology | 16/02/2026 | By News Bureau
Innovent Biologics and Eli Lilly Forge Strategic Collaboration in Oncology and Immunology
Innovent Biologics will receive USD 350 million upfront and up to USD 8.5 billion in milestones under a new global development pact, with Lilly securing ex-Greater China rights to novel oncology and immunology programmes.
Oncology | 10/02/2026 | By News Bureau
FIU Researchers Advance Functional Precision Medicine for Hard to Treat Cancers
FIU researchers are advancing functional precision medicine for hard-to-treat cancers, with new funding accelerating drug sensitivity testing to identify personalized, effective therapies beyond conventional genetic approaches.
Oncology | 22/01/2026 | By News Bureau
Harbour BioMed has exercised its warrant to acquire shares in Spruce Biosciences, securing a 3.8 percent stake and deepening their collaboration to advance SPR202 for rare endocrine and immune disorders.
Oncology | 19/01/2026 | By News Bureau | 103
BD Secures FDA 510(k) Clearance for EnCor EnCompass Multi-Modality Breast Biopsy System
BD has received FDA 510(k) clearance for its EnCor EnCompass multi-modality breast biopsy system, designed to improve procedural efficiency, clinician flexibility and early detection and diagnosis of breast disease.
Oncology | 17/01/2026 | By News Bureau | 101
Pierre Fabre, Iktos Partner on AI-Driven Oncology Drug Discovery Collaboration
The partnership between Pierre Fabre and Iktos integrates generative AI and automated chemistry to accelerate small-molecule cancer drug development.
Oncology | 09/01/2026 | By News Bureau | 124
Merck is set to showcase new data at ESMO 2025, highlighting advancements in oncology across emerging tumor types and early-stage diseases, with positive survival results from KEYNOTE-905 and KEYNOTE-B96 trials demonstrating the impact of KEYTRUDA (pembrolizumab) in bladder and ovarian cancers.
Oncology | 11/10/2025 | By Dineshwori | 778
Lilly Plans to Build USD 6.5 Billion Facility to Manufacture APIs in Texas
Eli Lilly will invest USD 6.5 billion to set up a new API manufacturing facility in Houston, Texas—its eighth US site since 2020—creating over 4,600 jobs and boosting domestic production of small molecule medicines.
Oncology, | 24/09/2025 | By Dineshwori | 258
Johnson and Johnson Reports Over 18 Percent Jump in Q2 Earnings
Johnson and Johnson has reported its second-quarter 2025 results, with net earnings soaring 18.2 percent to USD 5.54 billion, up from USD 4.69 billion in the same period last year.
Oncology | 17/07/2025 | By Dineshwori | 241
Innovent's DOVBLERON Secures Second NMPA Approval for ROS1-Positive NSCLC
China's National Medical Products Administration (NMPA) has approved the second New Drug Application (NDA) of DOVBLERON®, a next-generation ROS1 tyrosine kinase inhibitor (TKI).
Oncology | 03/01/2025 | By Abha | 261
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy